Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

Brijesh Arora, Ruben A. Mesa, Ayalew Tefferi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.

Original languageEnglish (US)
Pages (from-to)2373-2386
Number of pages14
JournalLeukemia and Lymphoma
Volume45
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Primary Myelofibrosis
Hematologic Neoplasms
Bone Marrow
Osteosclerosis
Angiogenesis Inhibitors
Therapeutic Uses
Therapeutics
Microvessels
Fibrosis
Collagen
Stem Cells

Keywords

  • Agnogenic myeloid metaplasia
  • Angiogenesis
  • Anti-antigenesis treatment
  • MPD
  • Myelofibrosis
  • Myelofibrosis therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. / Arora, Brijesh; Mesa, Ruben A.; Tefferi, Ayalew.

In: Leukemia and Lymphoma, Vol. 45, No. 12, 12.2004, p. 2373-2386.

Research output: Contribution to journalArticle

Arora, Brijesh ; Mesa, Ruben A. ; Tefferi, Ayalew. / Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 12. pp. 2373-2386.
@article{52a7e0e6de9a4c478c136315565a84db,
title = "Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia",
abstract = "Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.",
keywords = "Agnogenic myeloid metaplasia, Angiogenesis, Anti-antigenesis treatment, MPD, Myelofibrosis, Myelofibrosis therapy",
author = "Brijesh Arora and Mesa, {Ruben A.} and Ayalew Tefferi",
year = "2004",
month = "12",
doi = "10.1080/10428190400003267",
language = "English (US)",
volume = "45",
pages = "2373--2386",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

AU - Arora, Brijesh

AU - Mesa, Ruben A.

AU - Tefferi, Ayalew

PY - 2004/12

Y1 - 2004/12

N2 - Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.

AB - Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.

KW - Agnogenic myeloid metaplasia

KW - Angiogenesis

KW - Anti-antigenesis treatment

KW - MPD

KW - Myelofibrosis

KW - Myelofibrosis therapy

UR - http://www.scopus.com/inward/record.url?scp=11444256444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11444256444&partnerID=8YFLogxK

U2 - 10.1080/10428190400003267

DO - 10.1080/10428190400003267

M3 - Article

C2 - 15621750

AN - SCOPUS:11444256444

VL - 45

SP - 2373

EP - 2386

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -